TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06433960

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Allen Test
Description: Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 1 minute.~Instruct the patient to clench their wrist while the examiner occlude with three fingers the patients ulnar and radial arteries; instruct the patient to unclench their wrist; release the ulnar artery. The MAT result is negative or positive considering in how long the palm flushes:~≤5 seconds: negative MAT; good collateral hand circulation (suggesting harvestable radial artery).~greater than 5 seconds: positive MAT; poor collateral hand circulation (suggesting not-harvestable radial artery).

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse-oximetry guided Modified Allen Test
Description: Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 1 minute.~A pulse-oximetry probe is positioned on the patients index finger; both radial and ulnar arteries are occluded by the examiner (with three fingers) until flattening of pulse waveform is obtained. Pressure on the ulnar artery is released and the result of the assessment is calculated considering in how long the pulse waveform returns to baseline:~≤5 seconds: negative result (suggesting harvestable radial artery). greater than 5 seconds: positive result (suggesting not harvestable radial artery).~(Busti and Kellogg, 2015)

Intervention type: DIAGNOSTIC_TEST
Intervention: Barbeau Test
Description: Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 2 minutes.~A pulse-oximetry probe is positioned on the patients thumb; the radial artery is then compressed by the examiner, and the pulse waveform is analysed for up to 120 seconds, providing four result patterns of ulno-palmar patency:~1. No damping of the pulse tracing immediately after compression (suggesting harvestable radial artery)~2. Damping of the pulse tracing (suggesting harvestable radial artery)~3. Loss of the pulse tracing, followed by recovery within 120 sec (suggesting harvestable radial artery)~4. Loss of the pulse tracing, without recovery within 120 sec (suggesting not harvestable radial artery).~(Zalocar et al., 2020)
Study: NCT06504992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin 1000 MG
Description: Powdered, intrawound vancomycin 1000 mg at the time of definitive surgery for open fracture fixation in addition to the current best practice of intravenous antibiotics with irrigation and debridement
Study: NCT05235009

Intervention type: DIAGNOSTIC_TEST
Intervention: Combined free GAGome MCED test
Description: The combined free GAGome MCED test aggregates measurements of plasma and urine GAGomes (the exhaustive human glycosaminoglycan profile) into a diagnostic score, the combined free GAGome MCED score. The measurements are performed using MIRAM MCED Kits (Elypta AB) and the scores are computed using Elypta SKY Software (Elypta AB)

Intervention type: DIAGNOSTIC_TEST
Intervention: Combined free GAGome MCED test
Description: The combined free GAGome MCED test aggregates measurements of plasma and urine GAGomes (the exhaustive human glycosaminoglycan profile) into a diagnostic score, the combined free GAGome MCED score. The measurements are performed using MIRAM MCED Kits (Elypta AB) and the scores are computed using Elypta SKY Software (Elypta AB)
Study: NCT05783622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JANX008
Description: JANX008 is dosed via IV weekly in a 21-day cycle
Study: NCT06433960

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination of the forearm arteries
Description: Pre-operative intervention aimed at evaluating morphological characteristics (diameter, presence of calcifications) of the radial and ulnar arteries. Duration: 5 minutes.~The radial artery is surgically exposed (negative result) when the following apply:~1. ulnar artery inner diameter ≥2 mm~2. radial artery inner diameter ≥2 mm~3. absence of radial artery intraluminal calcifications and plaques.~(Vukovic et al., 2017)

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of oxygen saturation
Description: Intra-operative intervention aimed at evaluating the blood oxygen level in the hand if the radial artery was harvested. Duration: 1 minute.~The radial artery is surgically harvested when the oxygen saturation reading (SpO2) from the thumb through pulse-oximetry remains at 95% or above when an occlusive atraumatic clamp is applied on the mobilised radial artery.

Intervention type: OTHER
Intervention: Radial Artery Quality Evaluation Survey
Description: Intra-operative intervention (validated structured questionnaire) aimed at evaluating anatomical and physiological characteristics of the radial artery and suitability for coronary graft implantation.~The radial artery is surgically harvested when its morphology and pathology (diameter, calcifications, presence of pulsatile flow), quality of harvesting technique and surgical accessibility are considered satisfactory, good or optimal.~The Radial Artery Quality Evaluation Survey is completed by surgical care practitioners.
Study: NCT05783622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JANX008
Description: JANX008 is dosed via IV weekly in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JANX008
Description: JANX008 is dosed via IV weekly in a 21-day cycle
Study: NCT04971746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: On Days 1 and 13, participants will receive an oral dose of pirfenidone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4716
Description: From Day 3 to Day 14, participants will receive GLPG4716 daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4716
Description: From Day 3 to Day 14, participants will receive GLPG4716 daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: On Days 1 and 13, participants will receive an oral dose of nintedanib.
Study: NCT04854174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5
Description: Oral agent; 25 mg formulation
Study: NCT05822804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Closure Device (Tonbridge)
Description: Hemostasis treatment for femoral artery puncture with Vascular Closure Device (Tonbridge).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOSEAL Vascular Closure Device (Codis Corporation)
Description: Hemostasis treatment for femoral artery puncture with EXOSEAL Vascular Closure Device (Codis Corporation).
Study: NCT05636228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-102
Description: INV-102 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Ophthalmic Solution
Study: NCT06433960

Intervention type: OTHER
Intervention: Follow-up Radial Artery Harvesting Scale
Description: Postoperative intervention (ordinal symptoms scale) aimed at evaluating patients finger movements, cold tolerance sensitivity and tactile/touch perception at post-operative day 2 to 5 and at follow-up appointment (3-6 weeks after surgery). Bilateral comparison between hands and forearms is undertaken. Tactile perception is assessed through monofilaments (single touch). Cold sensitivity is assessed through the use of ice-pack.~The Follow-up Radial Artery Harvesting Scale was developed from a verbal rating scale (VRS) questionnaire documented in the literature. The VRS questionnaire was re-adapted to appreciate people postoperative experience with their finger movements, cold sensitivity and tactile/touch perception of their forearm.
Study: NCT05983211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Stage 2 \[CURRENTLY ENROLLING\]:~Accelerated rTMS using continuous theta burst stimulation (cTBS) inhibitory paradigms over bilateral M1 including hand, leg, and bulbar regions outputted at 90% of resting motor threshold, using bursts of 3 pulses at 50 Hz. Bursts are repeated at 5 Hz for a total of 600, 1200, 1800, or 3600 pulses over 40 seconds, 1 minute 20 seconds, 2 minutes, or 4 minutes. ALS patients will receive rTMS bilaterally for up to 8 treatment sessions per day, delivered one per hour, over 5 days, followed by single-day maintenance treatments at a frequency of every 2 weeks for 12 weeks, then every 4 weeks for 12 weeks.
Study: NCT06420947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: atomizer
Description: Participants received 2% lidocaine by atomizer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: atomizer
Description: Participants received 2% lidocaine by atomizer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: atomizer
Description: Participants received 2% lidocaine by atomizer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: atomizer
Description: Participants received 2% lidocaine by atomizer.
Study: NCT05722860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Citrulline, capsule
Description: 5g/daily dose for the duration of 1 week intervention
Study: NCT05902988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLS-1488
Description: VLS-1488 tablets will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLS-1488
Description: VLS-1488 tablets will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLS-1488
Description: VLS-1488 tablets will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLS-1488
Description: VLS-1488 tablets will be given orally.
Study: NCT06194864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: itraconazole 200 mg QD Days 6 to 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: rifampicin 600 mg QD Days 6 to 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: 89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: 89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2
Study: NCT06010654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Software as a Medical device
Description: The test device is a software medical device designed for the purpose of treating generalized anxiety disorder that provides self-talk training based on acceptance and commitment therapy (ACT). Use 2 sets per day for 10 weeks with generalized treatment of standard treatment method.
Study: NCT04181359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Study: NCT06113068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fistura® procedure
Description: The Fistura® procedure is performed using a sterile Fistura® catheter (F Care Systems), intended to be connected to an F Care Systems radiofrequency generator (MedRF4000®). The flexible Fistura® catheters used during the procedure allow it to follow the path of the anal fistula, facilitating the closure of the fistula along its entire length. As the catheter can treat fistulas involving the sphincter complex, but without cutting or damaging it, it is expected to be effective in term of continence maintenance.
Study: NCT04747041

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CYSCONTROL/PHYTOCYST Herbal tea
Description: Alternating every month from Day1 to Day15 cyscontrol and phytocyst herbal tea to prevent episode of cystitis
Study: NCT06180343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala
Description: Participants will be asked to choose the pages they want from the 12 colored felt-tip pen paint sets and mandala coloring book given to each participant by the researcher, and color them in the colors they want, for 6 weeks, once a week, at any time of the day and for an average of 20-30 minutes each time.~Participants will be asked to send a message before they start painting the mandala, and after the process, they will be asked to take a picture of the mandala they have painted and send it to the researcher. If the participants forget to color the mandala, a reminder message will be sent by the researcher twice a week.
Study: NCT05249556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Ganaxolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (for ganaxolone)
Study: NCT06142786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attenuating individualized lower alpha neurofeedback
Description: Real time visual feedback will be given the participants, such that as the higher/lower alpha power increases (relative to the mean value in the pre-training resting state EEG recording) a plane on the screen will move horizontally (the movement is correspondent to the magnitude of upper/lower alpha ratio), and the animation will change based on EEG parameter every 2 seconds. EMG-based feedback is also provided, such that if the children's EMG level is too high the plane will drop (vertical movement). Participants are instructed to 'fly' the plane as far as possible.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback
Description: The sham neurofeedback protocol was identical to the verum neurofeedback protocol except that the animation (horizontal plane movement) was based on the EEG results of another participant. EMG-based feedback will still be provided for the sham condition
Study: NCT06246292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided ESPB
Description: The ESPB is a truncal block guided by ultrasound, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomical landmark-guided ESPB
Description: The ESPB is a truncal block guided by anatomical landmarks, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.
Study: NCT06118021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20094
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20094
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20094
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20094
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study: NCT05310955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: daily rehabilitation interventions
Description: including Naikan therapy, Morita therapy, group art therapy, group painting therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: daily rehabilitation interventions
Description: including Naikan therapy, Morita therapy, group art therapy, group painting therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shen-based Qigong exercise
Description: a 12-week intervention of shen-based Qigong exercise : exercise 5 days a week, about 30 minutes a day
Study: NCT06474026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 4000 Type 2.1
Description: In Sham+Active arm, the subject will receive sham device application(Visit 2-1) and then active device application(Visit 2-2) after 7±2 days.~In Active arm, the subject will receive active device application(Visit 2)~Subjects will return to the site at Visit 3 (7±2 days post-active device application), Visit 4 (30±7 days post-active device application), Visit 5 (90±7 days post-active device application), and Visit 6 (180±7 days post-active device application) for safety and efficacy assessments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 4000 Type 2.1
Description: In Sham+Active arm, the subject will receive sham device application(Visit 2-1) and then active device application(Visit 2-2) after 7±2 days.~In Active arm, the subject will receive active device application(Visit 2)~Subjects will return to the site at Visit 3 (7±2 days post-active device application), Visit 4 (30±7 days post-active device application), Visit 5 (90±7 days post-active device application), and Visit 6 (180±7 days post-active device application) for safety and efficacy assessments.
Study: NCT05798494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: Subjects will receive dietary counseling by a dietitian from 3 months post-partum of the 1st child until birth of the 2nd child. The mother (and father if overweight, BMI ≥25 kg/m\^2) will receive advice to provide a moderate caloric restriction (-500 to 1000 kcal/d) and power walk 2-4 times a week for a half an hour and attend physical activity sessions every 2nd week to attain a minimum weight loss of approximately 0,5-1,0 kg/week. The weight loss will last until a 10% weight loss (according to pre-pregnancy weight) has been achieved or until 1-year post-partum. If the subject has not achieved a weight loss of 10%, she or he will receive Very low-calorie diet (VLCD) until target weight loss is reached, though no longer than 8 weeks. After weight loss subjects will receive counseling to maintain weight loss and healthy weight gain during pregnancy until birth of the 2nd child.
Study: NCT04885907

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273 vaccine
Description: COVID vaccine 3rd dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: Normal Saline Placebo
Study: NCT05799820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin injection
Description: 130mg/m2 administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
Study: NCT05637710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of investigation of Eurofarma drug
Description: Participants randomized to this group will receive one (01) film-coated tablet of the investigational drug + one (01) levocetirizine placebo tablet, once a day, for seven (07) days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Comparator
Description: Participants randomized to this group will receive one (01) levocetirizine 5mg tablet (Zina® 5mg) + one (01) FDC placebo tablet, once daily, for seven (07) days.
Study: NCT05577247

Intervention type: OTHER
Intervention: functional magnetic resonance imaging
Description: Patients treated with ketamine antidepressants will be tested with fMRI before or 24h after a single ketamine infusion administered in the clinical setting.

Intervention type: OTHER
Intervention: functional magnetic resonance imaging
Description: Patients treated with ketamine antidepressants will be tested with fMRI before or 24h after a single ketamine infusion administered in the clinical setting.
Study: NCT05324462

Intervention type: DRUG
Intervention: IDegLira
Description: Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
Study: NCT06502860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin to skin with sling
Description: In the intervention group, skin-to-skin contact will be facilitated using a specially designed sling. This approach aims to enhance the quality and duration of skin-to-skin contact between the mother and the newborn.
Study: NCT05979883

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Machine Learning Assisted Radiation (MLAP) RapidPlan
Description: Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist. The preliminary plan will be run through the RapidPlan module, which will give a list of possible improvements to the plan. The dosimetrist will then make an amendment to the plan according to RapidPlan suggestions, followed by plan change requests and approval by the physician.

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy Standard of Care (SOC)
Description: Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist, followed by plan change requests and approval by the physician.